Christian Jackisch

41.0k total citations · 6 hit papers
356 papers, 12.6k citations indexed

About

Christian Jackisch is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Christian Jackisch has authored 356 papers receiving a total of 12.6k indexed citations (citations by other indexed papers that have themselves been cited), including 262 papers in Oncology, 190 papers in Cancer Research and 115 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Christian Jackisch's work include Breast Cancer Treatment Studies (173 papers), HER2/EGFR in Cancer Research (145 papers) and Cancer Treatment and Pharmacology (105 papers). Christian Jackisch is often cited by papers focused on Breast Cancer Treatment Studies (173 papers), HER2/EGFR in Cancer Research (145 papers) and Cancer Treatment and Pharmacology (105 papers). Christian Jackisch collaborates with scholars based in Germany, Switzerland and United States. Christian Jackisch's co-authors include Gϋnter von Minckwitz, Michael Untch, Jens‐Uwe Blohmer, Holger Eidtmann, Sibylle Loibl, Jens Huober, J. Hilfrich, Serban Dan Costa, Manfred Kaufmann and Bernd Gerber and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Christian Jackisch

338 papers receiving 12.4k citations

Hit Papers

Definition and Impact of Pathologic Complete Response on ... 2006 2026 2012 2019 2012 2017 2006 2010 2021 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
    2012 1.8k citations Gϋnter von Minckwitz, Michael Untch et al. Journal of Clinical Oncology profile →
  2. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
    2017 688 citations David Cameron, Martine Piccart et al. The Lancet profile →
  3. Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
    2006 540 citations Ignace Vergote, Andreas du Bois et al. Journal of Clinical Oncology profile →
  4. Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
    2010 410 citations Éric Pujade-Lauraine, Uwe Wagner et al. Journal of Clinical Oncology profile →
  5. An Overview of PARP Inhibitors for the Treatment of Breast Cancer
    2021 241 citations Christian Jackisch et al. profile →
  6. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
    2022 136 citations Sibylle Loibl, Andreas Schneeweiß et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christian Jackisch Germany 52 8.5k 6.2k 2.2k 2.1k 1.8k 356 12.6k
Jens Huober Germany 47 8.6k 1.0× 6.0k 1.0× 1.9k 0.8× 1.7k 0.8× 3.3k 1.8× 321 12.1k
Jens‐Uwe Blohmer Germany 41 6.2k 0.7× 6.3k 1.0× 2.5k 1.1× 1.6k 0.8× 1.4k 0.8× 322 10.0k
P. Fumoleau France 61 9.6k 1.1× 4.4k 0.7× 1.1k 0.5× 2.3k 1.1× 2.7k 1.5× 326 14.3k
Elżbieta Senkus Poland 35 6.2k 0.7× 4.0k 0.6× 1.2k 0.5× 1.0k 0.5× 2.5k 1.4× 113 10.1k
André Robidoux Canada 36 7.7k 0.9× 8.0k 1.3× 4.1k 1.9× 1.1k 0.5× 1.5k 0.8× 89 14.7k
Bernard Asselain France 59 5.2k 0.6× 4.4k 0.7× 2.6k 1.2× 992 0.5× 2.1k 1.1× 323 11.0k
Sabino De Placido Italy 64 7.8k 0.9× 3.7k 0.6× 1.0k 0.5× 1.6k 0.8× 4.5k 2.5× 381 14.0k
Michael Untch Germany 65 12.6k 1.5× 10.1k 1.6× 3.5k 1.6× 3.9k 1.8× 3.7k 2.0× 542 19.7k
Nicole Rotmensz Italy 66 5.6k 0.7× 7.0k 1.1× 3.5k 1.6× 919 0.4× 1.5k 0.8× 223 12.0k
Charles E. Geyer United States 49 11.3k 1.3× 8.6k 1.4× 2.9k 1.3× 3.1k 1.5× 3.2k 1.7× 183 16.3k

Countries citing papers authored by Christian Jackisch

Since Specialization
Citations

This map shows the geographic impact of Christian Jackisch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christian Jackisch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christian Jackisch more than expected).

Fields of papers citing papers by Christian Jackisch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christian Jackisch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christian Jackisch. The network helps show where Christian Jackisch may publish in the future.

Co-authorship network of co-authors of Christian Jackisch

This figure shows the co-authorship network connecting the top 25 collaborators of Christian Jackisch. A scholar is included among the top collaborators of Christian Jackisch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christian Jackisch. Christian Jackisch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lüftner, Diana, Florian Schuetz, Andreas Schneeweiß, et al.. (2024). Efficacy and safety of everolimus plus exemestane in patients with hormone receptor‐positive, HER‐2‐negative advanced breast cancer: Results from the open‐label, multicentre, non‐interventional BRAWO study. International Journal of Cancer. 155(1). 128–138. 1 indexed citations
2.
Untch, Michael, Nina Ditsch, Peter A. Fasching, et al.. (2024). Discussion of ABC7 Consensus and German Recommendations. Geburtshilfe und Frauenheilkunde. 84(5). 431–442. 1 indexed citations
3.
Denkert, Carsten, Annette Lebeau, Hans‐Ulrich Schildhaus, Christian Jackisch, & Josef Rüschoff. (2022). New treatment options for metastatic HER2-low breast cancer. PubMed. 44(S2). 53–60. 9 indexed citations
4.
Kolberg, Hans‐Christian, et al.. (2021). Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review. The Breast. 57. 95–103. 7 indexed citations
5.
Jackisch, Christian, Patricia Cortazar, Charles E. Geyer, et al.. (2021). Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. Cancer Treatment Reviews. 99. 102229–102229. 12 indexed citations
6.
Pondé, Noam, Dominique Agbor‐Tarh, Lissandra Dal Lago, et al.. (2020). Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D). Breast Cancer Research and Treatment. 185(1). 107–116. 4 indexed citations
7.
Mackelenbergh, Marion van, Carsten Denkert, Valentina Nekljudova, et al.. (2017). Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Research and Treatment. 167(1). 59–71. 34 indexed citations
8.
Cameron, David, Martine Piccart, Richard D. Gelber, et al.. (2017). 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. The Lancet. 389(10075). 1195–1205. 688 indexed citations breakdown →
9.
Sonnenblick, Amir, Evandro de Azambuja, Dominique Agbor‐Tarh, et al.. (2016). Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. JNCI Journal of the National Cancer Institute. 108(8). djw037–djw037. 22 indexed citations
10.
Loibl, Sibylle, Silvia Darb‐Esfahani, Jens Huober, et al.. (2016). Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. Clinical Cancer Research. 22(11). 2675–2683. 34 indexed citations
11.
Metzger, Otto, Marion Procter, Evandro de Azambuja, et al.. (2013). Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial. Journal of Clinical Oncology. 31(16). 1954–1960. 30 indexed citations
12.
Azim, Hatem A., Dominique Agbor‐Tarh, Ian Bradbury, et al.. (2013). Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial. Journal of Clinical Oncology. 31(36). 4504–4511. 45 indexed citations
13.
14.
Pujade-Lauraine, Éric, Uwe Wagner, Val Gebski, et al.. (2010). Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. Journal of Clinical Oncology. 28(20). 3323–3329. 410 indexed citations breakdown →
15.
16.
Lux, Michael P., Michael Hartmann, Christian Jackisch, et al.. (2009). Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model. Breast Cancer Research and Treatment. 117(2). 305–317. 22 indexed citations
17.
Jackisch, Christian. (2006). HER-2-Positive Metastatic Breast Cancer: Optimizing Trastuzumab-Based Therapy. The Oncologist. 11(S1). 34–41. 44 indexed citations
18.
Rody, Achim, Raihanatou Diallo, Christopher Poremba, et al.. (2004). Estrogen receptor α and β, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast. Oncology Reports. 12(4). 695–9. 19 indexed citations
19.
Dittmar, Thomas, et al.. (1998). Selection of Potentially Metastatic Subpopulations Expressing c-erbB-2 from Breast Cancer Tissue by Use of an Extravasation Model. American Journal Of Pathology. 153(6). 1797–1806. 51 indexed citations
20.
Brandt, Burkhard, et al.. (1998). Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. International Journal of Cancer. 76(6). 824–828. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jens Huober Breakdown of academic impact, for papers by Jens‐Uwe Blohmer Breakdown of academic impact, for papers by P. Fumoleau Breakdown of academic impact, for papers by Elżbieta Senkus Breakdown of academic impact, for papers by André Robidoux Breakdown of academic impact, for papers by Bernard Asselain Breakdown of academic impact, for papers by Sabino De Placido Breakdown of academic impact, for papers by Michael Untch Breakdown of academic impact, for papers by Nicole Rotmensz Breakdown of academic impact, for papers by Charles E. Geyer
Rankless by CCL
2026